Adverum Biotechnologies Reports Positive 24-Week Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy to Treat Wet AMD

NEXT STORY
Wright Medical Group N.V. Highlights Recent Innovations and Clinical Data at the American Orthopaedic Foot & Ankle Society (AOFAS) 2019 Annual Meeting
PREV STORY
Roche’s satralizumab significantly reduced relapse risk in second positive phase III study for neuromyelitis optica spectrum
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Friends of Prentice Raises Nearly $600,000 at First-Ever Virtual Gala Benefitting Women’s Health

author_avatar
NASDAQ Market News

TESARO Provides Pipeline Update at ASCO Investor Briefing

Rolapitant IV NDA accepted for review by FDA; PDUFA date is January 11, 2017Sufficient ...

author_avatar
NASDAQ Market News

FDA Grants Bellerophon Emergency Expanded Access for INOpulse® for the Treatment of COVID-19 Virus

author_avatar
NASDAQ Market News